NCT01787331已完成2 期
Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA)
研究概览
简要总结
This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. To determine whether the proportion of patients who achieve a >= 50% decline in serum prostate-specific antigen (PSA) after 12 weeks of protocol therapy with itraconazole dosed at 300 mg orally (PO) twice daily (BID) is superior to a historical control based upon the observed PSA response proportion in prior studies of non-castrating systemic therapy in men with biochemically relapsed hormone sensitive prostate cancer.
SECONDARY OBJECTIVES:
I. To determine the median time to PSA progression from the start of protocol therapy with itraconazole among men with biochemically relapsed prostate cancer.
II. To determine the median time to clinical progression measured from the start of protocol therapy with itraconazole among men with biochemically relapsed prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologic confirmation of adenocarcinoma of the prostate
- •Biochemically relapsed disease with a rising PSA on at least two successive measurements at least two weeks apart after prior definitive local therapy (radical prostatectomy, external beam radiation, or brachytherapy) or combination of radical prostatectomy and radiotherapy (RT) with curative intent; if the confirmatory PSA value is less than the screening PSA value, then an additional test for rising PSA will be required to documents progression
- •Prior primary or salvage radiation or not a candidate for salvage radiation due to patient preference or clinical assessment based upon disease characteristics and/or patient co-morbidities
- •Minimum PSA:
- •If no prior androgen deprivation therapy (ADT) for biochemical relapse:
- •1.0 ng/mL if prior radical prostatectomy with or without adjuvant/salvage radiation therapy, confirmed by repeat measurement at least 2 weeks later, or
- •Nadir + 2 ng/mL if prior RT alone without prior radical prostatectomy, confirmed by repeat measurement at least 2 weeks later
- •If prior ADT for biochemical relapse:
- •4.0 ng/mL or > 2 ng/mL above nadir on prior cycle of ADT, whichever is higher, confirmed by repeat measurement at least 2 weeks later
- •No evidence of metastatic disease on imaging by whole body bone scan (technetium-99 or sodium fluoride [Na-F] positron emission tomography [PET] bone scan) and cross-sectional imaging of the abdomen/pelvis (computed tomography [CT] or magnetic resonance imaging [MRI]) within 6 weeks of day 1 of protocol therapy
- •Prior androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist and/or antagonist allowed for either (neo)adjuvant treatment with local therapy or for biochemical relapse
- •Last effective dose of LHRH agonist/antagonist ?expired? > 3 months prior to study entry; for example, a patient receiving LHRH agonist injection every 3 months would be eligible provided their last injection was > 6 months prior to day 1 of protocol therapy; a patient receiving LHRH agonist injections every 4 months will be eligible provided last injection was > 7 months prior to day 1 of protocol therapy
- •Serum testosterone level:
- •If no prior androgen deprivation therapy:
- •A single measurement greater than 150 ng/dL within 3 months of day 1 of protocol therapy
- •If prior androgen deprivation therapy (either in adjuvant or biochemical relapse setting):
- •The two most recent measurements of serum testosterone prior to day 1 of protocol therapy must fulfill the following criteria:
- •Both measurements are greater than 150 ng/dL
- •The two measurements are spaced at least 14 days apart
- •Both must be measured within 3 months of day 1 of protocol therapy
- •There must not be an increase of > 50 ng/dL between these two successive measurements
- •PSA doubling time (PSADT) =< 15 months, calculated based upon all serum PSA measurements obtained within 3 months prior to day 1 of protocol therapy, with a minimum of three PSA measurements spaced at least 14 days apart ; PSA values obtained when serum testosterone was known to be less than 150 ng/dL, prior to local therapy, or within three months of last dose of LHRH agonist/antagonist or antiandrogen will be excluded from the calculation of the PSADT
- •Total bilirubin less than 1.5 times upper limit of normal (ULN), or less than 3 times ULN at study entry in a patient with documented Gilbert?s disease
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 1.5 times ULN at study entry
- •Serum potassium greater than 3.5 mmol/L without oral supplementation
- •No history of uncontrolled hypertension (blood pressure > 160/100 mm Hg despite anti-hypertensive medication)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Estimated life expectancy greater than 5 years
- •Ability to sign written informed consent
- •Ability to swallow study drug whole as a capsule
- •Primary prostate cancer tissue available for analysis is not required for inclusion onto this study but is strongly encouraged
- •Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last study drug administration
排除标准
- •Castrate-resistant disease, as evidenced by either:
- •Rising PSA on 2 consecutive measurements at least 2 weeks apart with concurrent documented serum testosterone < 50 ng/dL at the time of PSA measurement, or
- •Rising PSA on 2 consecutive measurements at least 2 weeks apart measured within 3 months after last LHRH agonist/antagonist injection
- •Prior bilateral orchiectomy
- •Congestive heart failure of New York Heart Association (NYHA) class III or higher severity at study entry
- •History of chronic active hepatitis
- •Grade 2 or higher peripheral neuropathy at the time of study entry
- •Use of 5-alpha reductase antagonist (i.e. finasteride, dutasteride) or antiandrogen (i.e. flutamide, bicalutamide) within 6 weeks of day 1 of protocol therapy
- •Use of systemic steroids at an equivalent dose of prednisone 5 mg/day or higher within 6 weeks of day 1 of protocol therapy
- •Use of medications or herbal supplements which are known to potentially lower serum PSA within 6 weeks of day 1 of protocol therapy
- •Use of other medications that may potentially interact with itraconazole within 1 week of study entry
- •Use of other investigational agents within 6 weeks of day 1 of protocol therapy
- •Prior pathology consistent with small cell carcinoma or prostate cancer with predominantly neuroendocrine differentiation
研究组 & 干预措施
Treatment (itraconazole)
Experimental
Patients receive twice/day 300mg itraconazole (oral)
干预措施: Itraconazole (Drug)
Treatment (itraconazole)
Experimental
Patients receive twice/day 300mg itraconazole (oral)
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (itraconazole)
Experimental
Patients receive twice/day 300mg itraconazole (oral)
干预措施: Pharmacological Study (Other)
结局指标
主要结局
Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA)
时间窗: At 12 weeks after start of treatment
The number of patients with biochemically relapsed disease after prior definitive local therapy who achieve a ≥ 50% decline from baseline in serum PSA after 12 weeks of therapy with itraconazole, confirmed by repeat measurement at least 2 weeks later.
次要结局
- Median Time to Clinical Progression(Up to 2 years)
- Median Metastasis-free Survival(Up to 2 years)
- Percentage of Participants With Treatment-related, Adverse Changes in Vital Signs(Up to 2 years)
- Mean Steady-state Trough Level of Hydroxy-itraconazole(Up to 4 weeks)
- Median Time to PSA Progression(Up to 2 years)
- Mean Percent Change in PSA Doubling Time(Up to 12 weeks)
- Percentage of Participants With Treatment-related, Clinical Laboratory Adverse Events(Up to 2 years)
- Mean Steady-state Trough Level of Serum Itraconazole(Up to 4 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Intermittent itraconazole therapy for preventing asthma exacerbationsBronchial asthmaJPRN-UMIN000006311Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science60
已完成
1 期
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.HealthyNAFLDNCT04845646Gannex Pharma Co., Ltd.24
已完成
1 期
Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy SubjectsHealthyNCT04843449Ascletis Pharmaceuticals Co., Ltd.24
Unknown
早期 1 期
Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer PatientsEsophageal CancerNCT02749513Dallas VA Medical Center18
招募中
2 期
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's EsophagusBarrett EsophagusClinical Stage I Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Esophageal AdenocarcinomaNCT06732388National Cancer Institute (NCI)76